India's GLP-1 Boom Prompts Doctors to Urge Caution Against Unsupervised Self-Use
The Week reports that India's GLP-1 market is surging following semaglutide patent expiry in March, with doctors warning that self-medication — particularly through unapproved online channels — poses serious risks including pancreatitis and thyroid complications. Experts emphasize the need for clinical oversight and proper dose titration.